Stockscreener 앱 받기
684.50
0.04%
-0.27
시간 외 거래:
684.50
전일 마감가:
$684.77
열려 있는:
$681.66
하루 거래량:
334.24K
Relative Volume:
0.93
시가총액:
$42.36B
수익:
$4.16B
순이익/손실:
$1.29B
주가수익비율:
34.95
EPS:
19.586
순현금흐름:
$734.26M
1주 성능:
-3.44%
1개월 성능:
-19.21%
6개월 성능:
-7.09%
1년 성능:
+10.41%
1일 변동 폭
$678.99
$687.17
1주일 범위
$678.99
$716.25
52주 변동 폭
$510.06
$934.62
알제넥스 NV ADR Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-12-18 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 재개 | Truist | Buy |
| 2025-09-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics - GlobeNewswire Inc.
TD Cowen reiterates argenx stock Buy rating on growth outlook By Investing.com - Investing.com India
TD Cowen reiterates argenx stock Buy rating on growth outlook - Investing.com
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal - Investing.com South Africa
Forecasting The Future: 16 Analyst Projections For argenx - Sahm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Finviz
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock - Finviz
Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - marketscreener.com
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - ChartMill
Argenx Benefits From Strong Growth for Vyvgart; Pipeline Continues to Make Progress - Morningstar
Oppenheimer raises argenx stock price target to $1,060 on sales growth - Investing.com
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
Citizens raises argenx stock price target on ocular MG results - Investing.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Lantheus (LNTH) - The Globe and Mail
argenx Q4 2025 slides: first profitable year, 90% revenue surge By Investing.com - Investing.com Australia
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com India
argenx Q4 2025 slides: first profitable year, 90% revenue surge - Investing.com South Africa
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
ARGENX : Barclays reiterates its Buy rating - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
Argenx reports $1.3 billion in Q4 global product net sales - marketscreener.com
Argenx: Positive topline results from phase 3 adapt oculus trial of Vyvgart in oMG - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx Says Phase 3 Study of Ocular Myasthenia Gravis Therapy Met Main Goal - marketscreener.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Insights into argenx's Upcoming Earnings - Sahm
Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART - Insider Monkey
argenx to Present at TD Cowen 46th Annual Healthcare Conference - ChartMill
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 - Sahm
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz
Wells Fargo analyst sees potential in Argenx SE’s (ARGX) Vyvgart, increases PT to $1,317 - MSN
Goldman Sachs Assumes Penguin Solutions (PENG) Coverage with Buy Rating, $25 PT - Yahoo Finance
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Insider Monkey
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Yahoo Finance
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds - Yahoo Finance
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW) - Yahoo Finance
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.15%
자본화:
|
볼륨(24시간):